Intensive-Dose Tinzaparin in Hospitalized COVID-19 Patients: The INTERACT Study.

ABSTRACT: (1) Background: It is well-established that coronavirus disease-2019 (COVID-19) is highly pro-inflammatory, leading to activation of the coagulation cascade. COVID-19-induced hypercoagulability is associated with adverse outcomes and mortality. Current guidelines recommend that hospitalized COVID-19 patients should receive pharmacological prophylaxis against venous thromboembolism (VTE). (2) INTERACT is a retrospective, phase IV, observational cohort study aiming to evaluate the overall clinical effectiveness and safety of a higher than conventionally used prophylactic dose of anticoagulation with tinzaparin administered for VTE prevention in non-critically ill COVID-19 patients with moderate disease severity. (3) Results: A total of 705 patients from 13 hospitals in Greece participated in

SUBMITTER: Akinosoglou K 

PROVIDER: S-EPMC9027745 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature